About Sudarshan Pharma Industries Limited
Data last updated:
Sudarshan Pharma Industries Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the scientific services segment of the professional services sector. It was incorporated on 23 July 2008 and has been in existence for over 18 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L51496MH2008PLC184997. Its GSTIN is 27AAMCS2601L1Z6 (Maharashtra). The company holds 6 GST registrations, of which 4 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 543828.
The company has an authorised share capital of ₹35 Cr and a paid-up capital of ₹25.45 Cr. It was formerly known as Sudarshan Pharma Industries Private Limited and Sudarshan Speciality Chemsolve Private Limited. It is led by directors including Sachin Vasantrai Mehta (Managing Director) and Hemal Vasantrai Mehta (Managing Director).
Its last annual general meeting (AGM) was held on 25 July 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 301 3rd Floor Aura Biplex Above Kalyan Jewellers S. V. Road Borivali (West), Mumbai, Maharashtra, India – 400092.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹703.06 Cr, a growth of 39.2% compared to the previous year. For the same year it recorded a net profit of ₹23.31 Cr (net margin 3.3%) and EBITDA of ₹51.32 Cr (EBITDA margin 7.3%). The net worth stands at ₹155.1 Cr (up 17.7% YoY). Total assets are valued at ₹441.89 Cr (up 44% YoY).
The company has about 9 employees on its provident fund (EPFO) records. Its group structure includes 3 subsidiaries.
The company is associated with 2 brands: Farm2energy and Sudarshan Pharma. As per MCA filings, the company has open charges of ₹324.21 Cr and satisfied charges of ₹104.81 Cr on record. Court records list 14 cases involving the company, including 8 filed by the company and 6 filed against it; 9 cases are pending. The company has 42 deals on record (34 market trades, 4 funding rounds, 2 rights issues), with disclosed funding of ₹35.1 Cr; the latest was in February 2025. The company has 14 MSME Form 1 returns on record between 2015 and 2024, listing 83 overdue payments to 41 micro and small suppliers.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website sudarshanpharma.com.
Company details
Name history
Sudarshan Pharma Industries has undergone 2 name changes throughout its history. The company was previously known as Sudarshan Pharma Industries Private Limited, and Sudarshan Speciality Chemsolve Private Limited. The current legal name is Sudarshan Pharma Industries Limited.
| Company Name | Status |
|---|---|
| Sudarshan Pharma Industries Limited | Current |
| Sudarshan Pharma Industries Private Limited | Previous |
| Sudarshan Speciality Chemsolve Private Limited | Previous |
CIN history
Sudarshan Pharma Industries has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L51496MH2008PLC184997, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L51496MH2008PLC184997 | Current |
| U51496MH2008PTC184997 | Previous |
| U51496MH2008PLC184997 | Previous |
Contact details
Sudarshan Pharma Industries Limited's registered office is in Mumbai, Maharashtra. Its website is sudarshanpharma.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address301 3rd Floor Aura Biplex Above Kalyan Jewellers S. V. Road Borivali (West), Mumbai, Maharashtra, India – 400092
- IndustryProfessional Services, Scientific, Technical, Personal
To see the full contact details of Sudarshan Pharma Industries Limited, buy the company report.
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Brands
Sudarshan Pharma Industries operates two associated brands: Farm2energy and Sudarshan Pharma. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| Offers online slot gaming with jackpots and integrated e-commerce features for users. | farm2energy.com | |
| Sudarshan Pharma is engaged in manufacturing pharmaceuticals and specialty chemicals. | sudarshanpharma.com |
Business activity
The main business activities of Sudarshan Pharma Industries are trade and professional, scientific and technical. In detail, this covers wholesale trading and other professional, scientific and technical activities. 2 activity segments are registered with the MCA.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| G | Trade | G1 | Wholesale Trading | |
| M | Professional, Scientific and Technical | M9 | Other professional, scientific and technical activities |
To see the full business activity and turnover split of Sudarshan Pharma Industries Limited, buy the company report.
Financials of Sudarshan Pharma Industries Limited
FY 2025-26 filings availableSudarshan Pharma Industries Limited reported revenue of ₹703.06 Cr (up 39.2% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 703 | 505 | 464 | 461 | 357 | 193 | 148 |
| Revenue growth | +39.2% | +9.0% | +0.5% | +29.2% | +84.7% | +30.7% | - |
| EBITDA | 51.32 | 37.11 | 22.81 | 14.68 | 10.92 | 7.16 | 4.76 |
| EBITDA margin | +7.3% | +7.4% | +4.9% | +3.2% | +3.1% | +3.7% | +3.2% |
| Profit before tax | 30.54 | 21.64 | 15.24 | 9.49 | 7.13 | 3.57 | 1.71 |
| Net profit | 23.31 | 18.03 | 11.46 | 7.21 | 5.32 | 2.66 | 1.27 |
| Net profit margin | +3.3% | +3.6% | +2.5% | +1.6% | +1.5% | +1.4% | +0.9% |
| EPS (₹) | 0.97 | 0.66 | 4.76 | 2.92 | 5.38 | 2.80 | 1.34 |
| Balance sheet | |||||||
| Total assets | 442 | 307 | 217 | 135 | 60.41 | 52.35 | 40.66 |
| Net worth | 155 | 132 | 112 | 101 | 29.78 | 22.51 | 19.84 |
| Total debt | 285 | 175 | 105 | 34.10 | 30.60 | 29.77 | 20.81 |
| Cash & bank | 1.13 | 0.55 | 0.14 | 11.72 | 0.24 | 1.25 | 1.27 |
| Net working capital | 291 | 226 | 174 | 101 | 52.62 | 40.86 | 29.38 |
| Cash flow | |||||||
| Cash from operations | (2.30) | (32.32) | 6.01 | (28.79) | (3.82) | 2.77 | 0.51 |
| Cash from investing | (76.29) | (20.62) | (5.49) | (25.65) | (1.46) | (1.29) | (2.53) |
| Cash from financing | 79.17 | 53.35 | (12.10) | 65.93 | 4.26 | (1.49) | (0.28) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 174 | 221 | 168 | 169 | 145 | 162 | 116 | 129 |
| Revenue growth (YoY) | +20.1% | +36.7% | +45.3% | +31.3% | +46.4% | - | - | - |
| Other income | 1.22 | 4.13 | 1.52 | 1.86 | 1.21 | 0.84 | 0.51 | 0.32 |
| EBITDA | 15.90 | 20.20 | 10.87 | 9.21 | 11.04 | 14.28 | 7.98 | 11.87 |
| EBITDA margin | +9.1% | +9.1% | +6.5% | +5.5% | +7.6% | +8.8% | +6.9% | +9.2% |
| Depreciation | 1.41 | 1.09 | 0.91 | 0.90 | 0.88 | 0.83 | 0.63 | 0.67 |
| Interest | 8.21 | 7.53 | 6.28 | 5.94 | 5.96 | 4.40 | 4.00 | 3.70 |
| Profit before tax | 7.50 | 15.71 | 5.20 | 4.23 | 5.41 | 9.89 | 3.86 | 7.82 |
| Tax | 1.90 | 4.31 | 1.05 | 0.36 | 1.45 | 2.48 | 0.96 | 1.95 |
| Net profit | 5.60 | 11.40 | 4.15 | 3.87 | 3.96 | 7.41 | 2.90 | 5.87 |
| EPS (₹) | 0.23 | 0.47 | 0.18 | 0.16 | 0.16 | 0.29 | 0.12 | 0.24 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 668 | 503 | 466 | 461 | 357 | 193 | 148 |
| Revenue growth | +32.8% | +7.9% | +0.9% | +29.2% | +84.7% | +30.7% | - |
| EBITDA | 48.97 | 35.69 | 22.59 | 14.68 | 10.93 | 7.28 | 4.76 |
| EBITDA margin | +7.3% | +7.1% | +4.9% | +3.2% | +3.1% | +3.8% | +3.2% |
| Profit before tax | 28.66 | 21.30 | 15.08 | 9.49 | 7.14 | 3.58 | 1.71 |
| Net profit | 21.97 | 17.98 | 11.34 | 7.21 | 5.33 | 2.67 | 1.27 |
| Net profit margin | +3.3% | +3.6% | +2.4% | +1.6% | +1.5% | +1.4% | +0.9% |
| EPS (₹) | 0.90 | 0.66 | 4.72 | 2.93 | 5.39 | 2.80 | 1.34 |
| Balance sheet | |||||||
| Total assets | 436 | 308 | 219 | 135 | 60.40 | 52.30 | 40.66 |
| Net worth | 153 | 131 | 112 | 101 | 29.78 | 22.51 | 19.84 |
| Total debt | 282 | 177 | 107 | 34.10 | 30.59 | 29.78 | 20.81 |
| Cash & bank | 0.11 | 0.39 | 0.13 | 11.71 | 0.23 | 1.15 | 1.27 |
| Net working capital | 286 | 229 | 173 | 101 | 52.51 | 40.72 | 29.38 |
| Cash flow | |||||||
| Cash from operations | (2.75) | (33.18) | 9.69 | (28.79) | (3.70) | 2.67 | 0.51 |
| Cash from investing | (79.71) | (20.24) | (9.08) | (25.65) | (1.54) | (1.35) | (2.53) |
| Cash from financing | 82.18 | 53.68 | (12.18) | 65.93 | 4.31 | (1.44) | (0.28) |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 166 | 200 | 158 | 167 | 142 | 162 | 116 | 124 |
| Revenue growth (YoY) | +16.4% | +23.7% | +37.0% | +35.1% | +39.9% | - | - | - |
| Other income | 1.35 | 3.21 | 1.69 | 2.09 | 1.41 | 0.91 | 0.57 | 0.59 |
| Total expenses | 149 | 182 | 148 | 157 | 132 | 148 | 108 | 112 |
| EBITDA | 16.27 | 18.30 | 10.77 | 9.61 | 10.28 | 13.56 | 7.96 | 11.23 |
| EBITDA margin | +9.8% | +9.2% | +6.8% | +5.8% | +7.2% | +8.4% | +6.9% | +9.1% |
| Depreciation | 1.29 | 1.00 | 0.81 | 0.81 | 0.79 | 0.76 | 0.66 | 0.65 |
| Interest | 8.19 | 7.27 | 6.24 | 6.07 | 5.71 | 4.44 | 4.05 | 3.96 |
| Profit before tax | 8.14 | 13.24 | 5.41 | 4.82 | 5.19 | 9.27 | 3.82 | 7.21 |
| Tax | 2.10 | 3.69 | 1.11 | 0.43 | 1.46 | 2.25 | 1.08 | 1.81 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 174 | 221 | 168 | 169 | 145 | 162 | 116 | 129 |
| Revenue growth (YoY) | +20.1% | +36.7% | +45.3% | +31.3% | +46.4% | - | - | - |
| Other income | 1.22 | 4.13 | 1.52 | 1.86 | 1.21 | 0.84 | 0.51 | 0.32 |
| EBITDA | 15.90 | 20.20 | 10.87 | 9.21 | 11.04 | 14.28 | 7.98 | 11.87 |
| EBITDA margin | +9.1% | +9.1% | +6.5% | +5.5% | +7.6% | +8.8% | +6.9% | +9.2% |
| Depreciation | 1.41 | 1.09 | 0.91 | 0.90 | 0.88 | 0.83 | 0.63 | 0.67 |
| Interest | 8.21 | 7.53 | 6.28 | 5.94 | 5.96 | 4.40 | 4.00 | 3.70 |
| Profit before tax | 7.50 | 15.71 | 5.20 | 4.23 | 5.41 | 9.89 | 3.86 | 7.82 |
| Tax | 1.90 | 4.31 | 1.05 | 0.36 | 1.45 | 2.48 | 0.96 | 1.95 |
| Net profit | 5.60 | 11.40 | 4.15 | 3.87 | 3.96 | 7.41 | 2.90 | 5.87 |
| EPS (₹) | 0.23 | 0.47 | 0.18 | 0.16 | 0.16 | 0.29 | 0.12 | 0.24 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 703 | 505 | 464 | 461 | 357 | 193 | 148 |
| Revenue growth | +39.2% | +9.0% | +0.5% | +29.2% | +84.7% | +30.7% | - |
| Other income | 8.71 | 2.52 | 2.61 | 1.12 | 0.46 | 0.38 | 0.02 |
| Total expenses | 652 | 468 | 441 | 447 | 346 | 186 | 143 |
| Employee cost | 0.00 | 3.45 | 2.68 | 2.08 | 1.68 | 1.38 | 1.50 |
| EBITDA | 51.32 | 37.11 | 22.81 | 14.68 | 10.92 | 7.16 | 4.76 |
| EBITDA margin | +7.3% | +7.4% | +4.9% | +3.2% | +3.1% | +3.7% | +3.2% |
| Depreciation | 3.79 | 2.22 | 1.24 | 0.91 | 0.87 | 0.74 | 0.35 |
| Interest | 25.70 | 15.77 | 8.94 | 5.40 | 3.38 | 3.23 | 2.72 |
| Profit before tax | 30.54 | 21.64 | 15.24 | 9.49 | 7.13 | 3.57 | 1.71 |
| Tax | 7.16 | 5.68 | 3.78 | 2.46 | 1.88 | 0.91 | 0.44 |
| Net profit | 23.31 | 18.03 | 11.46 | 7.21 | 5.32 | 2.66 | 1.27 |
| Net profit margin | +3.3% | +3.6% | +2.5% | +1.6% | +1.5% | +1.4% | +0.9% |
| EPS (₹) | 0.97 | 0.66 | 4.76 | 2.92 | 5.38 | 2.80 | 1.34 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.07 | 24.07 | 24.07 | 24.07 | 9.75 | 9.55 | 9.55 |
| Reserves & surplus | 127 | 104 | 87.64 | 76.91 | 20.03 | 12.96 | 10.29 |
| Shareholders' funds (net worth) | 155 | 132 | 112 | 101 | 29.78 | 22.51 | 19.84 |
| Minority interest | 1.22 | 0.00 | 0.00 | 0.00 | 0.00 | 0.05 | 0.00 |
| Secured loans | 226 | 147 | 68.98 | 31.04 | 27.38 | 4.36 | 14.70 |
| Unsecured loans | 59.38 | 27.23 | 35.86 | 3.06 | 3.22 | 25.41 | 6.11 |
| Total debt | 285 | 175 | 105 | 34.10 | 30.60 | 29.77 | 20.81 |
| Total liabilities | 442 | 307 | 217 | 135 | 60.41 | 52.35 | 40.66 |
| Assets | |||||||
| Gross block | 110 | 50.31 | 29.33 | 22.45 | 8.49 | 7.64 | 6.32 |
| Net block | 104 | 47.50 | 25.50 | 19.89 | 6.46 | 6.22 | 5.64 |
| Capital work in progress | 3.44 | 22.54 | 1.88 | 0.01 | 0.54 | 0.00 | 0.00 |
| Investments | 0.00 | 1.67 | 13.84 | 12.34 | 0.00 | 0.00 | 0.04 |
| Inventories | 219 | 140 | 85.74 | 74.57 | 46.87 | 23.96 | 17.38 |
| Sundry debtors | 233 | 153 | 123 | 81.51 | 73.48 | 60.39 | 26.87 |
| Cash & bank balances | 1.13 | 0.55 | 0.14 | 11.72 | 0.24 | 1.25 | 1.27 |
| Loans & advances | 37.05 | 32.14 | 31.64 | 30.83 | 9.00 | 2.03 | 1.34 |
| Total current assets | 490 | 326 | 240 | 199 | 130 | 87.63 | 46.86 |
| Total current liabilities | 200 | 99.33 | 66.48 | 97.16 | 76.97 | 46.77 | 17.48 |
| Net working capital | 291 | 226 | 174 | 101 | 52.62 | 40.86 | 29.38 |
| Total assets | 442 | 307 | 217 | 135 | 60.41 | 52.35 | 40.66 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.55 | 0.14 | 11.72 | 0.24 | 1.25 | 1.27 | 3.56 |
| Net cash from operating activities | (2.30) | (32.32) | 6.01 | (28.79) | (3.82) | 2.77 | 0.51 |
| Net cash from investing activities | (76.29) | (20.62) | (5.49) | (25.65) | (1.46) | (1.29) | (2.53) |
| Net cash from financing activities | 79.17 | 53.35 | (12.10) | 65.93 | 4.26 | (1.49) | (0.28) |
| Net change in cash | 0.58 | 0.41 | (11.58) | 11.48 | (1.02) | (0.01) | (2.29) |
| Closing cash | 1.13 | 0.55 | 0.14 | 11.72 | 0.24 | 1.25 | 1.27 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +39.2% | +9.0% | +0.5% | +29.2% | +84.7% | +30.7% | - |
| EBITDA growth | +38.3% | +62.7% | +55.4% | +34.4% | +52.5% | +50.4% | - |
| PBT growth | +41.1% | +42.0% | +60.6% | +33.1% | +99.7% | +108.8% | +9997.0% |
| Net income growth | +29.3% | +57.3% | +59.0% | +35.5% | +100.0% | +109.5% | - |
| Revenue CAGR (3Y) | +15.1% | +12.3% | +33.8% | +46.1% | - | - | - |
| EBITDA CAGR (3Y) | +51.8% | +50.4% | +47.1% | +45.6% | - | - | - |
| Profitability & leverage | |||||||
| Net income margin | +3.3% | +3.2% | +2.5% | +1.5% | +1.5% | +1.4% | +0.9% |
| Return on capital employed | - | +15.5% | +13.7% | +15.2% | +18.7% | +14.6% | +10.9% |
| Return on net worth | - | +14.8% | +10.8% | +10.8% | +20.1% | +12.6% | +6.5% |
| Debt / equity | - | 1.13 | 0.65 | 0.49 | 1.15 | 1.19 | 1.05 |
| Long-term debt / equity | - | 0.09 | 0.11 | 0.14 | 0.20 | 0.29 | 0.35 |
| Interest cover | 54.07 | 45.20 | 41.45 | 39.22 | 33.63 | 50.31 | 61.68 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 17.30 | 17.90 | 29.82 | 44.28 | 27.70 | 23.41 |
| Inventory turnover | - | 4.47 | 5.78 | 7.60 | 10.08 | 9.35 | 8.51 |
| Debtors turnover | - | 3.57 | 4.54 | 5.95 | 5.33 | 4.43 | 5.51 |
| EPS (₹) | 0.97 | 0.66 | 4.76 | 2.92 | 5.38 | 2.80 | 1.34 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.30 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 5.30 | 46.42 | 41.96 | 30.54 | 23.58 | 20.78 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 166 | 200 | 158 | 167 | 142 | 162 | 116 | 124 |
| Revenue growth (YoY) | +16.4% | +23.7% | +37.0% | +35.1% | +39.9% | - | - | - |
| Other income | 1.35 | 3.21 | 1.69 | 2.09 | 1.41 | 0.91 | 0.57 | 0.59 |
| Total expenses | 149 | 182 | 148 | 157 | 132 | 148 | 108 | 112 |
| EBITDA | 16.27 | 18.30 | 10.77 | 9.61 | 10.28 | 13.56 | 7.96 | 11.23 |
| EBITDA margin | +9.8% | +9.2% | +6.8% | +5.8% | +7.2% | +8.4% | +6.9% | +9.1% |
| Depreciation | 1.29 | 1.00 | 0.81 | 0.81 | 0.79 | 0.76 | 0.66 | 0.65 |
| Interest | 8.19 | 7.27 | 6.24 | 6.07 | 5.71 | 4.44 | 4.05 | 3.96 |
| Profit before tax | 8.14 | 13.24 | 5.41 | 4.82 | 5.19 | 9.27 | 3.82 | 7.21 |
| Tax | 2.10 | 3.69 | 1.11 | 0.43 | 1.46 | 2.25 | 1.08 | 1.81 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 668 | 503 | 466 | 461 | 357 | 193 | 148 |
| Revenue growth | +32.8% | +7.9% | +0.9% | +29.2% | +84.7% | +30.7% | - |
| Other income | 8.40 | 2.88 | 2.75 | 1.12 | 0.46 | 0.27 | 0.02 |
| Total expenses | 619 | 467 | 443 | 447 | 346 | 186 | 143 |
| Employee cost | 0.00 | 3.12 | 2.54 | 2.08 | 1.68 | 1.38 | 1.50 |
| EBITDA | 48.97 | 35.69 | 22.59 | 14.68 | 10.93 | 7.28 | 4.76 |
| EBITDA margin | +7.3% | +7.1% | +4.9% | +3.2% | +3.1% | +3.8% | +3.2% |
| Depreciation | 3.41 | 1.31 | 1.23 | 0.91 | 0.87 | 0.74 | 0.35 |
| Interest | 25.30 | 15.96 | 9.03 | 5.40 | 3.38 | 3.23 | 2.72 |
| Profit before tax | 28.66 | 21.30 | 15.08 | 9.49 | 7.14 | 3.58 | 1.71 |
| Tax | 6.69 | 5.41 | 3.74 | 2.46 | 1.88 | 0.91 | 0.44 |
| Net profit | 21.97 | 17.98 | 11.34 | 7.21 | 5.33 | 2.67 | 1.27 |
| Net profit margin | +3.3% | +3.6% | +2.4% | +1.6% | +1.5% | +1.4% | +0.9% |
| EPS (₹) | 0.90 | 0.66 | 4.72 | 2.93 | 5.39 | 2.80 | 1.34 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 24.07 | 24.07 | 24.07 | 24.07 | 9.75 | 9.55 | 9.55 |
| Reserves & surplus | 125 | 103 | 87.55 | 76.92 | 20.03 | 12.96 | 10.29 |
| Shareholders' funds (net worth) | 153 | 131 | 112 | 101 | 29.78 | 22.51 | 19.84 |
| Secured loans | 224 | 147 | 68.98 | 31.40 | 27.38 | 25.72 | 14.70 |
| Unsecured loans | 58.22 | 29.26 | 37.91 | 2.70 | 3.21 | 4.06 | 6.11 |
| Total debt | 282 | 177 | 107 | 34.10 | 30.59 | 29.78 | 20.81 |
| Total liabilities | 436 | 308 | 219 | 135 | 60.40 | 52.30 | 40.66 |
| Assets | |||||||
| Gross block | 99.50 | 45.03 | 24.36 | 22.45 | 8.49 | 7.64 | 6.32 |
| Net block | 94.25 | 42.33 | 20.57 | 19.89 | 6.46 | 6.22 | 5.64 |
| Capital work in progress | 3.44 | 22.54 | 1.88 | 0.01 | 0.54 | 0.00 | 0.00 |
| Investments | 7.75 | 4.84 | 16.94 | 12.44 | 0.10 | 0.09 | 0.04 |
| Inventories | 207 | 137 | 84.37 | 74.57 | 46.87 | 23.96 | 17.38 |
| Sundry debtors | 199 | 152 | 123 | 81.51 | 73.48 | 60.39 | 26.87 |
| Cash & bank balances | 0.11 | 0.39 | 0.13 | 11.71 | 0.23 | 1.15 | 1.27 |
| Loans & advances | 38.75 | 35.27 | 31.78 | 30.73 | 8.90 | 1.99 | 1.34 |
| Total current assets | 445 | 325 | 239 | 199 | 129 | 87.49 | 46.86 |
| Total current liabilities | 158 | 95.40 | 65.87 | 97.16 | 76.97 | 46.77 | 17.48 |
| Net working capital | 286 | 229 | 173 | 101 | 52.51 | 40.72 | 29.38 |
| Total assets | 436 | 308 | 219 | 135 | 60.40 | 52.30 | 40.66 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 0.39 | 0.13 | 11.71 | 0.23 | 1.15 | 1.27 | 3.56 |
| Net cash from operating activities | (2.75) | (33.18) | 9.69 | (28.79) | (3.70) | 2.67 | 0.51 |
| Net cash from investing activities | (79.71) | (20.24) | (9.08) | (25.65) | (1.54) | (1.35) | (2.53) |
| Net cash from financing activities | 82.18 | 53.68 | (12.18) | 65.93 | 4.31 | (1.44) | (0.28) |
| Net change in cash | (0.28) | 0.26 | (11.58) | 11.48 | (0.93) | (0.11) | (2.29) |
| Closing cash | 0.11 | 0.39 | 0.13 | 11.71 | 0.23 | 1.15 | 1.27 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | +32.8% | +7.9% | +0.9% | +29.2% | +84.7% | +30.7% | - |
| EBITDA growth | +37.2% | +58.0% | +53.9% | +34.3% | +50.1% | +52.9% | - |
| PBT growth | +34.6% | +41.3% | +58.9% | +32.9% | +99.4% | +109.4% | -47.7% |
| Net income growth | +22.2% | +58.6% | +57.3% | +35.3% | +99.6% | +110.2% | - |
| Revenue CAGR (3Y) | +13.1% | +12.1% | +34.0% | +46.1% | +36.9% | +29.9% | +38.8% |
| EBITDA CAGR (3Y) | +49.4% | +48.4% | +45.9% | +45.6% | +36.1% | +141.0% | +98.4% |
| Profitability & leverage | |||||||
| Net income margin | +3.3% | +3.2% | +2.4% | +1.5% | +1.5% | +1.4% | +0.9% |
| Return on capital employed | - | +15.3% | +13.6% | +15.2% | +18.7% | +14.6% | +12.0% |
| Return on net worth | - | +14.8% | +10.7% | +10.8% | +20.1% | +12.6% | +6.6% |
| Debt / equity | - | 1.15 | 0.66 | 0.49 | 1.15 | 1.19 | 0.91 |
| Long-term debt / equity | - | 0.09 | 0.11 | 0.14 | 0.20 | 0.36 | 0.30 |
| Interest cover | 55.53 | 46.42 | 42.28 | 39.22 | 33.60 | 49.39 | 61.68 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 20.40 | 19.89 | 29.82 | 36.12 | 27.70 | 34.41 |
| Inventory turnover | - | 4.54 | 5.86 | 7.60 | 10.08 | 9.35 | 10.65 |
| Debtors turnover | - | 3.55 | 4.55 | 5.95 | 5.33 | 4.43 | 5.61 |
| EPS (₹) | 0.90 | 0.66 | 4.72 | 2.93 | 5.39 | 2.80 | 1.34 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.30 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 5.30 | 46.38 | 41.96 | 30.55 | 23.58 | 20.78 |
To see the full year-wise statements and ratios of Sudarshan Pharma Industries Limited, buy the company report.
Board of directors of Sudarshan Pharma Industries Limited
Sudarshan Pharma Industries has 7 current directors and 18 former directors. Current directors are listed first, with their designation and appointment date.
Auditor
Sudarshan Pharma Industries Limited is audited by NGST & Associates for the financial year 2024.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| NGST & Associates | FY 2024 | 135159W |
Shareholding
Shareholding for the quarter ended Sep 2026: promoters hold 58.90%, foreign institutional investors hold 19.40%, domestic institutional investors hold 0.00% and retail and other public shareholders hold 21.70%.
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | |
|---|---|---|---|---|
| Promoters | 58.90% | 57.40% | 57.40% | 57.40% |
| Public | 41.10% | 42.60% | 42.60% | 42.60% |
Charges & borrowings
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 27 Aug 2026 | 101400769 | Others | ₹20 Cr | Open | |
| 07 Aug 2026 | 101367514 | Karnataka Bank Ltd. | ₹1.99 Cr | Open | |
| 30 Jul 2026 | 101378786 | Others | ₹2 Cr | Open | |
| 22 Jul 2026 | 101346986 | Canara Bank | ₹35 Cr | Open | |
| 21 Jul 2026 | 101372324 | Indian Bank | ₹5.99 Cr | Open |
To see the full charge records of Sudarshan Pharma Industries Limited, buy the company report.
Total charge records: 31 View all charges
Deals & funding
Sudarshan Pharma Industries Limited has 42 deals on record (34 market trades, 4 funding rounds, 2 rights issues), with disclosed funding of ₹35.1 Cr; the latest was in February 2025.
Deals on record (5 of 42)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2025 | Market trade | ₹5.54 Cr | Buyer: Setu Securities Private Limited Seller: Mansi Share and Stock Broking Private Limited |
| Sep 2024 | Market trade | ₹8.18 Cr | Buyer: Epitome Trading And Investments, Shyamsakha Broking Services Private Limited Seller: Shyamsakha Broking Services Private Limited , Epitome Trading And Investments |
| Sep 2024 | Market trade | ₹14.78 Cr | Buyer: Mansi Share and Stock Broking Private Limited , Setu Securities Private Limited , Epitome Trading And Investments, an individual Seller: Setu Securities Private Limited , Epitome Trading And Investments, Mansi Share and Stock Broking Private Limited |
| Sep 2024 | Market trade | ₹30.02 Cr | Buyer: Globalworth Securities Limited Seller: G G Engineering Limited , 2 individuals |
| Sep 2024 | Market trade | ₹5.75 Cr | Buyer: an individual Seller: Multiplier Share and Stock Advisors Private Limited |
To see the full deal history of Sudarshan Pharma Industries Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Sudarshan Pharma Industries Limited has 14 court cases on record: 8 filed by Sudarshan Pharma Industries, 6 filed against it. 9 cases are pending and 5 are disposed.
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 12 | 4 | 9 |
| High courts | 2 | 2 | 0 |
Cases on record (5 of 14)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Vadodara, Gujarat | Commercial matter | Filed against the company by Chemcon Speciality Chemicals Ltd. Through Its Authorized Representative Rajeshbhai Chimanlal Gandhi | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (Summary Cases) | Filed against the company by Mersaco Chemicals Pvt Ltd Through Its Director Ashish Mehta | Pending |
| District court, Mumbai CMM Courts, Maharashtra | Court case (SS CASES S) | Filed by the company against Sonachi Industries Ltd | Pending |
| Bombay High Court | Court case (COMIP) | Filed against the company by Blue Cross Laboratories Private Limited | Disposed |
| Bombay High Court | Interim or miscellaneous application | Filed against the company by Blue Cross Laboratories Private Limited | Disposed |
To see the full case history of Sudarshan Pharma Industries Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
Sudarshan Pharma Industries Limited has 14 MSME Form 1 returns on record between 2015 and 2024, listing 83 overdue payments to 41 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.
Suppliers with reported dues (5 of 41)
| Supplier | Amount due | Due since | Reported on |
|---|---|---|---|
| M M Solvochem LLP | |||
| an individual supplier | |||
| Mehk Chemicals Pvt Ltd | |||
| an individual supplier | |||
| an individual supplier |
To see the full MSME payment records of Sudarshan Pharma Industries Limited, buy the company report.
Individuals and sole proprietors among the suppliers are not named.
Group structure & subsidiaries
Sudarshan Pharma Industries has 3 subsidiary companies. This group structure data is as of FY 2024. The table lists each entity with its relationship and holding.
| Company Name | CIN | Shares held |
|---|---|---|
| Life Science Chemical Private Limited | U21001GJ2023PTC144108 | |
| Sudarshan Pharma Lifescience Private Limited | U24299MH2021PTC357350 | |
| Ratna Lifesciences Private Limited | U74999PN2017PTC168995 |
To see the full group structure of Sudarshan Pharma Industries Limited, buy the company report.
Employees & EPFO
Sudarshan Pharma Industries Limited has a workforce of 9 employees on its EPFO records as of Mar 27, 2025, across 1 active EPFO establishment.
GST
Sudarshan Pharma Industries has 6 GST registrations: 4 active and 2 cancelled or inactive.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAMCS2601L1Z6 | Maharashtra | Active | 01 Jul 2017 |
| 24AAMCS2601L1ZC | Gujarat | Active | 01 Jul 2017 |
| 05AAMCS2601L1ZC | Uttarakhand | Active | 26 Nov 2022 |
| 06AAMCS2601L1ZA | Haryana | Active | 07 Nov 2024 |
To see the full GST registrations and return filing status of Sudarshan Pharma Industries Limited, buy the company report.
Recent activity
Sudarshan Pharma Industries Limited has 42 board changes on record since 2008: 25 appointments and 17 cessations. The latest: Vinay Kumar Pandey was appointed as Director on 01 May 2026.
86 earlier events are in the company report.
News
Frequently asked questions
Sudarshan Pharma Industries is an active public limited company based in Mumbai, Maharashtra, India. The company works in scientific, within the professional services industry. It was incorporated on 23 July 2008 (18+ years old) and is registered under CIN L51496MH2008PLC184997. Listed on BSE: 543828.
Sudarshan Pharma Industries reported revenue of ₹703.06 Cr for FY 2025-26 (up 39.2% YoY) based on consolidated financials.
Sudarshan Pharma Industries has 7 current directors:
- Sachin Vasantrai Mehta - Managing Director
- Hemal Vasantrai Mehta - Managing Director
- Jaya Ankur Singhania - Director
- Vijay Ojha - Director
- Anil Balkrishna Ghogare - Director
- Rushabh Prashant Patil - Director
- Vinay Kumar Pandey - Director
The latest financial statements of Sudarshan Pharma Industries on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 July 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Sudarshan Pharma Industries is 27AAMCS2601L1Z6, registered in Maharashtra. The company has 6 GST registrations in all, of which 4 are active and 2 are cancelled or inactive. Other active GSTINs include 24AAMCS2601L1ZC (Gujarat), 05AAMCS2601L1ZC (Uttarakhand), 06AAMCS2601L1ZA (Haryana).
The CIN (Corporate Identification Number) of Sudarshan Pharma Industries is L51496MH2008PLC184997. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Sudarshan Pharma Industries is a listed company as per MCA records. Its shares are listed on BSE (code: 543828).
Sudarshan Pharma Industries has 14 court cases on record: 8 filed by the company and 6 filed against it. 9 are pending. Most are in the district courts.
Sudarshan Pharma Industries was incorporated on 23 July 2008, making it 18+ years old. It is registered with the Registrar of Companies, Mumbai.
Sudarshan Pharma Industries has 42 deals on record (34 market trades, 4 funding rounds, 2 rights issues), with disclosed funding of ₹35.1 Cr; the latest was in February 2025.
Vinay Kumar Pandey was appointed as Director on 01 May 2026. Umesh Luthra ceased to be Director on 18 Oct 2025. Vijay Ojha was appointed as Director on 18 Oct 2025. Sudarshan Pharma Industries has 42 board changes on record in total.